Education
About Us
Working with TipRanks
Follow Us
Roivant Sciences Ltd. (ROIV)
:ROIV
ROIV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.93 - $13.06
Previous CloseN/A
Volume1.46M
Average Volume (3M)5.99M
Market Cap
$7.70B
Enterprise Value$3.85B
Total Cash (Recent Filing)$1.99B
Total Debt (Recent Filing)$100.31M
Price to Earnings (P/E)1.9
Beta0.91
Next Earnings
Jun 25, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding713,549,440
10 Day Avg. Volume8,492,676
30 Day Avg. Volume5,988,423
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)78.92
Price to Cash Flow (P/CF)-9.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit39.73
Enterprise Value/Ebitda0.87
Forecast
1Y Price Target
$44.25Price Target Upside310.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Roivant Sciences News
PremiumCompany Announcements
Roivant Sciences Engages Former Officer for Advisory Role
PremiumCompany Announcements
Roivant Sciences Announces Positive Results for Batoclimab Studies
PremiumCompany Announcements
Roivant Sciences Appoints New Chief Accounting Officer---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsBatoclimab demonstrated compelling absolute efficacy, setting a new high-water mark for biologics.
Investment ConfidenceRoivant recently increased its ownership in Immunovant to ~57%, signaling confidence in the prospects of IMVT-1402.
Product LaunchIMVT-1402 appears set to be first to market in Graves’ disease, and ROIV CEO Matt Gline stated that 1402 could be ahead of competitors in 1-2 'yet to announce' indications and 'neck & neck' in a number of indications.
Bears Say
Investor OverlookBrepocitinib's data is very likely to work and is largely overlooked by investors with a sizable commercial opportunity.
Market ExpectationsExpectations are relatively low for the batoclimab Ph3 gMG data as the results are intended to inform Ph3 trial design for IMVT-1402.
---
Ownership Overview
26.19% Insiders
13.37% Mutual Funds
42.27% Other Institutional Investors
4.02% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ROIV FAQ
What was Roivant Sciences Ltd.’s price range in the past 12 months?
Roivant Sciences Ltd. lowest stock price was $9.93 and its highest was $13.05 in the past 12 months.
What is Roivant Sciences Ltd.’s market cap?
Roivant Sciences Ltd.’s market cap is $7.70B.
When is Roivant Sciences Ltd.’s upcoming earnings report date?
Roivant Sciences Ltd.’s upcoming earnings report date is Jun 25, 2025 which is in 93 days.
How were Roivant Sciences Ltd.’s earnings last quarter?
Roivant Sciences Ltd. released its earnings results on Feb 10, 2025. The company reported -$0.203 earnings per share for the quarter, beating the consensus estimate of -$0.253 by $0.05.
Is Roivant Sciences Ltd. overvalued?
According to Wall Street analysts Roivant Sciences Ltd.’s price is currently Undervalued.
Does Roivant Sciences Ltd. pay dividends?
Roivant Sciences Ltd. does not currently pay dividends.
What is Roivant Sciences Ltd.’s EPS estimate?
Roivant Sciences Ltd.’s EPS estimate is -0.26.
How many shares outstanding does Roivant Sciences Ltd. have?
Roivant Sciences Ltd. has 713,549,440 shares outstanding.
What happened to Roivant Sciences Ltd.’s price movement after its last earnings report?
Roivant Sciences Ltd. reported an EPS of -$0.203 in its last earnings report, beating expectations of -$0.253. Following the earnings report the stock price went down -0.918%.
Which hedge fund is a major shareholder of Roivant Sciences Ltd.?
Currently, no hedge funds are holding shares in ROIV
---
Roivant Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.25 (310.10% Upside)
$44.25 (310.10% Upside)
Blogger Sentiment
Bullish
ROIV Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 7.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $22.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 10.9%
Last 30 Days ▼ 10.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
5.16%
12-Months-Change
Fundamentals
Return on Equity
-7.10%
Trailing 12-Months
Asset Growth
-20.79%
Trailing 12-Months
Company Description
Roivant Sciences Ltd.
Montes Archimedes Acquisition Corp is a blank check company.
---
ROIV Company Deck
---
ROIV Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Roivant Sciences Ltd. discussed a strong financial position and a promising pipeline with several upcoming clinical milestones. However, the company faces challenges in ongoing litigation and a competitive landscape in certain areas.Read More>---
ROIV Stock 12 Month Forecast
Average Price Target
$44.25
▲(310.10% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Ionis Pharmaceuticals
―
Vertex Pharmaceuticals
―
Biohaven Ltd.
―
Best Analysts Covering ROIV
1 Year
1 Year Success Rate
18/23 ratings generated profit
1 Year Average Return
+44.33%
reiterated a buy rating last month
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 78.26% of your transactions generating a profit, with an average return of +44.33% per trade.
---